Press Releases

Emmaus Medical Announces Completion of Enrollment for its Phase 3 Sickle Cell Disease TrialDecember 03, 2012

Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Company’s Phase III FDA Sickle Cell Treatment TrialsNovember 22, 2012

News-Medical.net Insights from IndustryOctober 26, 2012

Emmaus Life Sciences Issues Statement In Response to Announcement by AFH Holding & AdvisoryOctober 10, 2012

Emmaus Life Sciences, Inc., a specialty pharmaceutical and regenerative medicine company, today issued the following statement in response to an announcement issued October 9, 2012, by AFH Holding & Advisory, LLC.

Emmaus Medical Marks Progression of Phase 3 Sickle Cell Disease Clinical TrialSeptember 14, 2012

TORRANCE, Calif., September 13, 2012 –In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.